AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals, Inc. (AMLX) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Value (C+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C+ (2.5) | C+ (2.7) | B- (2.9) | B (3.4) | C+ (2.6) | C+ (2.8) |
| 2026-11-10 | C+ (2.5) | C+ (2.8) | B- (2.9) | A (4.3) | C+ (2.6) | B- (3.0) |
| 2026-11-03 | C+ (2.5) | C (2.3) | C+ (2.8) | A (4.4) | C+ (2.7) | B- (2.9) |
| 2026-10-27 | C+ (2.5) | C (2.2) | C+ (2.8) | A (4.4) | C+ (2.6) | B- (2.9) |
| 2026-10-20 | C+ (2.5) | C (2.2) | C+ (2.8) | A+ (4.6) | C+ (2.6) | B- (3.0) |